Drug research

INBRX-106

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Hexavalent OX40 agonist antibody

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCNCT06295731	INBX	Phase 2, Phase 3	Active not recruiting	2029-05Estimated

INBXActive not recruitingPrimary completion: 2029-05 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.